
Academic Journal
Q1MedComm
About MedComm
MedComm is a scholarly journal published by John Wiley and Sons Inc. SCImago 2025 lists it in Q1, with an SJR of 2.93 and H-index of 57.
Coverage: 2020-2026. Research categories: Biochemistry (medical) (Q1); Cell Biology (Q1); Drug Discovery (Q1); Genetics (Q1); Genetics (clinical) (Q1); Immunology and Allergy (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Immune cells in cancer; RNA modifications and cancer; SARS-CoV-2 and COVID-19 Research; Epigenetics and DNA Methylation; Ferroptosis and cancer prognosis.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Alveolar Macrophages: Development, Respiratory Homeostasis, Signal Pathways, Diseases, and Therapeutic Opportunities
Sihan Yang, Ruomeng Li, Chuanjiang Yu, Jing Li et al.
2026-10 · DOI: 10.1002/mco2.71031Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang et al.
2026-10 · DOI: 10.1002/mco2.71026A State‐Resolved Single‐Cell and Spatial Atlas Reveals IDH ‐Associated Differences in Malignant and Immune Architecture in Diffuse Glioma
Ashraf Zaman, Emily Holton, Madhavi Pandya, Genevieve Shillington et al.
2026-10 · DOI: 10.1002/mco2.71022Maturation‐Dependent Constraints in the Ability of Human Monocytes to Initiate Trained Immunity
Michael Eigenschink, Elsa Davogg, Manuel Pristner, David Seki et al.
2026-10 · DOI: 10.1002/mco2.70939Liver Metastases from Colorectal Cancer: From Pathogenesis to Current Treatment
Jialiang Fan, Huiru Zhang, Deyang Kong, Yu Sun et al.
2026-10 · DOI: 10.1002/mco2.71044All‐Oral PI3Kδ and HDAC Inhibition with Parsaclisib Plus Chidamide and Step‐Down Maintenance in Relapsed or Refractory Peripheral T‐Cell Lymphoma: A Phase Ib Trial
Xufeng Luo, Zheng Yan, Wei Fang, Hanchi Duan et al.
2026-10 · DOI: 10.1002/mco2.70993Iron and Other Metal Ions in Human Health and Disease
Xiaofeng Dai, Jitian Li
2026-10 · DOI: 10.1002/mco2.71021Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases
Miao Sun, Dengju Li, Jia Wei
2026-10 · DOI: 10.1002/mco2.71029Machine Learning‐Driven Noninvasive Prediction of Liver Fibrosis in Unclassified Liver Disease
Ye Yang, Yirui Hu, Ting Wei, Yue Chen et al.
2026-10 · DOI: 10.1002/mco2.70990Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2‐Low Breast Cancer
Xiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang et al.
2026-10 · DOI: 10.1002/mco2.70988Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy
Pin Guo, Yizhao Xie, Rui Song, Mengdi Yang et al.
2026-10 · DOI: 10.1002/mco2.71040G Protein‐Coupled Receptor in High‐Altitude Diseases: Mechanistic Insights and Therapeutic Opportunities
Qing Zhao, Changliang Liu, Lu Dai, Kun Zheng et al.
2026-10 · DOI: 10.1002/mco2.71033Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian et al.
2026-10 · DOI: 10.1002/mco2.71028Envonalkib Versus Crizotinib in Treatment‐Naive ALK ‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study
Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min et al.
2026-10 · DOI: 10.1002/mco2.70998Organoids: Current Applications and Future Directions
Yueqi Leng, Yue Wang, Canhui Cao, Feng Deng et al.
2026-10 · DOI: 10.1002/mco2.70965Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Shanshan Qi, Weiwei Chen, Kunhao Chen, Song Yang et al.
2026-10 · DOI: 10.1002/mco2.70956Cholesterol 25‐Hydroxylase Deficiency Provides an Optimal and Durable Protective T Helper 1 Immunity via Interleukin‐12–Interleukin‐2 Axis in BCG‐Vaccinated Mice
Hagyu Kim, Eunsol Choi, Kee Woong Kwon, Hong‐Hee Choi et al.
2026-10 · DOI: 10.1002/mco2.70989Presenilin 1 Mutations Converge on Aβ42/Aβ40 Elevation via Distinct Mechanisms
Isabel Bestard‐Lorigados, Keenan Sterling, Liwei Li, Zhehao Lin et al.
2026-10 · DOI: 10.1002/mco2.70978Posttranslational Modifications of p62/SQSTM1 in Health and Disease
Weikai Wang, Xin Jiang, Runing Qiu, Chandra Sugiarto Wijaya et al.
2026-10 · DOI: 10.1002/mco2.70949Reviews
Community Reviews
Version History
October 4, 2026 at 8:44 pm
September 16, 2026